GSK inks Russia vaccines deal with Binnopharm

GlaxoSmithKline has signed a deal which will see JSC Binnopharm manufacture a number of its vaccines in Russia.

Specifically the UK drugs major will supply bulk vaccine and provide technology and expertise to enable Binnopharm to undertake the secondary manufacture, including filling and packaging, of a number of GSK products. The Zelenograd, Moscow-based firm will be responsible for getting its facilities up to scratch in terms of meeting international current Good Manufacturing Practice standards and getting regultory approval to supply GSK’s cervical cancer vaccine Cervarix, Rotarix (rotavirus) and the pneumococcal vaccine Synflorix under Binnopharm’s trademark for the Russian market.

Commenting on the deal, the financial details for which have not been disclosed, Abbas Hussain, president of emerging markets and Asia Pacific at GSK, said it is “an example of the flexible approach we are taking to make innovative vaccines more available in emerging markets through local partnerships. Binnopharm’s general manager Maxim Uvarovclaimed the alliance “is a testament to the continued investment in our existing facilities “and the quality of its staff and management.

He concluded that “our aim through signing this partnership agreement is to create a leading biotechnology company in Russia”.